Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

MAGMA Targeting tertiary lymphoid structures using magneto-margination

Coordinator
Universite De Caen Normandie, France
Runs
1 June 2025 to 31 May 2030
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101170501

What the project is doing

In the project's own words, from its summary on CORDIS.

Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues that drive immune responses at sites of chronic inflammation. They are of widespread interest in biology and medicine since their presence dramatically influences disease course in autoimmune disorders, infection, and cancer. However, due to their small size and their development in chronically altered tissues, TLS cannot be selectively targeted or detected by imaging.

The current project aims at developing new methods to map and eventually destroy the TLS in a non-invasive manner. To this aim, a new formulation of injectable superparamagnetic particles will be produced and targeted to the TLS. A set of innovations in contrast agent design and material chemistry will be developed to dramatically increase targeting efficiency compared to existing methods. By combining these innovations, intravenously injected superparamagnetic particles will accumulate in TLS in large numbers, thereby allowing their non-invasive detection by clinically available imaging modalities (magnetic resonance imaging) and emerging technologies (magnetic particle imaging).

This will also open the possibility of thermal destruction of TLS using magnetic hyperthermia, providing a way to suppress a local immune response without affecting systemic immunity. The scientific advances and technologies of the MAGMA project will have clinically relevant applications, such as diagnosis of chronic inflammation, selection of patients for treatment with immune checkpoint inhibitors in cancer and spatially selective suppression of immunity in autoimmune diseases.

Topics

Who is involved

OrganisationCityCountryRole
Universite De Caen NormandieCaen Cedex 5FranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI